Koninklijke Philips N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 nov 2005 - 18:58
Statutaire naam
Koninklijke Philips N.V.
Titel
SCHERING AND PHILIPS TEAM UP IN NEW FIELD OF OPTICAL IMAGING FOR THE PREVENTION AND TREATMENT OF BREAST CANCER
Bericht
November 28, 2005
SCHERING AND PHILIPS TEAM UP IN NEW FIELD OF OPTICAL IMAGING FOR THE PREVENTION AND TREATMENT OF BREAST CANCER
Partners collaborate to develop contrast agents and medical equipment for the emerging optical imaging market
First development project – focused on mammography – in Phase I clinical trials
Amsterdam, The Netherlands and Berlin, Germany – Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today the formation of an alliance to research, develop and commercialize medical equipment and associated contrast agents for optical imaging. As part of their collaboration, the companies will have the option to expand the alliance to cover other imaging technologies and contrast agents, where synergies between the partners are expected, and will also explore the emerging field of molecular imaging. Philips and Schering have agreed to split equally all research and development costs as well as all future revenues from the contrast agents, medical equipment and related services related to this alliance. Financial details of the alliance were not disclosed.
Optical imaging is an emerging imaging technology with the potential to offer new approaches in the prevention and treatment of breast cancer as well as other diseases. Optical imaging uses lasers to illuminate superficial tissue – such as breast tissue. By combining this technology with an optical dye, tumors might be targeted more precisely. Due to its high resolution and sensitivity, optical imaging is expected to offer breast cancer patients a less aggressive, more patient-friendly follow-up examination. Today, such patients may need to undergo the invasive procedure of a biopsy in cases where traditional exams produce inconclusive results.
“We are very excited to team up with a leader in the contrast agent industry. Schering has strong capabilities in pharmaceutical R&D, and is clearly out in front in the new field of contrast a
Datum laatste update: 29 juli 2024